AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8041178 — intervention group
Group type: COMPARATOR
Intervention: Corn oil placebo
Number of subjects: 28
Study 2738212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy
Number of subjects: 66
Study 2738212 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral bibliotherapy
Number of subjects: 66
Study 2738212 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control
Number of subjects: 66
Study 1098732 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl)
Number of subjects: 218
Study 1098732 — intervention group
Group type: COMPARATOR
Intervention: Nimorazole (Naxogin)
Number of subjects: 218
Study 31329189 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex non-drug programs including exercise therapy, mineral water, multivitamins, minerals, and physiotherapy (vibrotherapy, chromotherapy, melotherapy, aromatherapy, aeroionotherapy)
Number of subjects: 330
Study 31329189 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex non-drug programs including vibrotherapy, chromotherapy, melotherapy, aromatherapy, and aeroionotherapy
Number of subjects: 330
Study 31329189 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 330
Study 27900515 — intervention group
Group type: EXPERIMENTAL
Intervention: AFEP enhanced with the '10 Keys'™ to Healthy Aging
Number of subjects: 462
Study 27900515 — intervention group
Group type: COMPARATOR
Intervention: AFEP alone
Number of subjects: 462
Study 26002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical LLETZ operation
Number of subjects: 0
Study 26002493 — intervention group
Group type: COMPARATOR
Intervention: Resection of the lesion only
Number of subjects: 0
Study 24431855 — intervention group
Group type: EXPERIMENTAL
Intervention: Open rhinoplasty
Number of subjects: 36
Study 24431855 — intervention group
Group type: COMPARATOR
Intervention: Closed rhinoplasty
Number of subjects: 36
Study 21816868 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 1094
Study 21816868 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1094
Study 19796594 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidine‐iodine 1% with isopropyl alcohol 23%
Number of subjects: 50
Study 19796594 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.5% with isopropyl alcohol 70%
Number of subjects: 50
Study 19796594 — intervention group
Group type: COMPARATOR
Intervention: Bristled brush pre-treatment
Number of subjects: 50
Study 16839845 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH1-24 1 mg IM, daily for 4 days
Number of subjects: 30
Study 16839845 — intervention group
Group type: COMPARATOR
Intervention: Cortisol 150 mg ID (50 mg tid) daily for 4 days
Number of subjects: 30
Study 16839845 — intervention group
Group type: COMPARATOR
Intervention: Control group observed for 4 days
Number of subjects: 30
Study 15486187 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (75 mg/m² q3wks)
Number of subjects: 108
Study 15486187 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (100 mg/m² q3wks)
Number of subjects: 108
Study 15486187 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 108
Study 15486187 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (topo-II tumor content >10%)
Number of subjects: 108
Study 15486187 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-2 status
Number of subjects: 108
Study 11305983 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 125
Study 11305983 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 125
Study 11305983 — intervention group
Group type: COMPARATOR
Intervention: Overall population (diabetics vs nondiabetics)
Number of subjects: 125
Study 11305983 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 125
Study 11305983 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 125
Study 9310126 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim 10 micrograms/kg
Number of subjects: 32
Study 9310126 — intervention group
Group type: COMPARATOR
Intervention: filgrastim 10 micrograms/kg
Number of subjects: 32
Study 7680995 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.9 g piracetam
Number of subjects: 5
Study 7680995 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 g piracetam
Number of subjects: 5
Study 7680995 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.6 g piracetam
Number of subjects: 5
Study 7680995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3535660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclacillin
Number of subjects: 80
Study 3535660 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 80
Study 3535660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 80
Study 29426677 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone (ALF)
Number of subjects: 10
Study 29426677 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 10
Study 29426677 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone + Acepromazine and Butorphanol (ALF–AB)
Number of subjects: 10
Study 29426677 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Acepromazine and Butorphanol (PRO–AB)
Number of subjects: 10
Study 29426677 — intervention group
Group type: COMPARATOR
Intervention: Acepromazine and Butorphanol (AB)
Number of subjects: 10
Study 26590067 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training on porcine cadaver
Number of subjects: 22
Study 26590067 — intervention group
Group type: COMPARATOR
Intervention: Traditional training per routine residency rotations
Number of subjects: 22
Study 25182161 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure lowering treatment
Number of subjects: 0
Study 25182161 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure
Number of subjects: 0
Study 22364430 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Skills: Working with Mental Illness training program delivered on the Internet, duration 8 weeks
Number of subjects: 0
Study 22364430 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20557392 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case management programme (comprehensive education and 6-week nurse-initiated telephone follow-up)
Number of subjects: 85
Study 20557392 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital discharge services (control group)
Number of subjects: 85
Study 18543037 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP)
Number of subjects: 24
Study 18543037 — intervention group
Group type: COMPARATOR
Intervention: Surgery with postoperative chemotherapy alone (previously studied controls)
Number of subjects: 24
Study 16317129 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher length-for-age and weight-for-length Z-scores, no anemia, and meat consumption
Number of subjects: 485
Study 16317129 — intervention group
Group type: COMPARATOR
Intervention: Lower length-for-age and weight-for-length Z-scores, presence of anemia, and no meat consumption
Number of subjects: 485
Study 12744488 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day enalapril for 5 days
Number of subjects: 30
Study 12744488 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 20 mg enalapril 2 h before LPS infusion
Number of subjects: 30
Study 12744488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11223318 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 21
Study 11223318 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective treatment included in trial protocol
Number of subjects: 21
Study 11223318 — intervention group
Group type: COMPARATOR
Intervention: Protocol/Hawthorne effect
Number of subjects: 21
Study 9551704 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan alone (160 mg)
Number of subjects: 12
Study 9551704 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg)
Number of subjects: 12
Study 9551704 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 1 h after cimetidine
Number of subjects: 12
Study 7938284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 29
Study 7938284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 29
Study 7938284 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 29
Study 2451385 — intervention group
Group type: COMPARATOR
Intervention: Local UVB irradiation
Number of subjects: 0
Study 2451385 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body UVB irradiation combined with additional irradiation of the hands
Number of subjects: 0
Study 30704214 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tract reconstruction group (n=41)
Number of subjects: 84
Study 30704214 — intervention group
Group type: COMPARATOR
Intervention: Double-tract reconstruction group (n=43)
Number of subjects: 84
Study 30704214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 29065953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (1, 2.5, 5, 10, 15, 25 mg)
Number of subjects: 291
Study 29065953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (doses > 1 mg)
Number of subjects: 291
Study 29065953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (2.5-10 mg)
Number of subjects: 291
Study 29065953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 25495490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian suppression
Number of subjects: 3066
Study 25495490 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 3066
Study 25495490 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian suppression
Number of subjects: 3066
Study 25495490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian suppression (in patients who received prior chemotherapy)
Number of subjects: 3066
Study 25495490 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (in patients who received prior chemotherapy)
Number of subjects: 3066
Study 22939048 — intervention group
Group type: EXPERIMENTAL
Intervention: Team and leaders‐directed strategy
Number of subjects: 2733
Study 22939048 — intervention group
Group type: COMPARATOR
Intervention: State‐of‐the‐art strategy
Number of subjects: 2733
Study 22939048 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both strategies
Number of subjects: 2733
Study 21731866 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day
Number of subjects: 80
Study 21731866 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 80
Study 19379098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide dry-mist disinfection system
Number of subjects: 748
Study 19379098 — intervention group
Group type: COMPARATOR
Intervention: 0.5% sodium hypochlorite solution
Number of subjects: 748
Study 16489082 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent docetaxel plus vaccine
Number of subjects: 28
Study 16489082 — intervention group
Group type: COMPARATOR
Intervention: Vaccine alone
Number of subjects: 28
Study 15038906 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife examination
Number of subjects: 826
Study 15038906 — intervention group
Group type: COMPARATOR
Intervention: Senior House Officer (SHO) examination
Number of subjects: 826
Study 11202309 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with multimodal therapy including chemotherapy
Number of subjects: 3696
Study 11202309 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 3696
Study 11202309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 3696
Study 9148719 — intervention group
Group type: EXPERIMENTAL
Intervention: Odstock dropped foot stimulator (ODFS)
Number of subjects: 56
Study 7918155 — intervention group
Group type: EXPERIMENTAL
Intervention: rhSOD (200 mg intravenously during surgery)
Number of subjects: 100
Study 31676953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus FOLFIRI
Number of subjects: 529
Study 29457429 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiletto needle treatment once a week for 2 weeks
Number of subjects: 113
Study 29457429 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife treatment once a week for 2 weeks
Number of subjects: 113
Study 29457429 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren treatment (votalin emulsion smearing 3 to 5 cm on painful area of knee joint, three times a day for 2 weeks)
Number of subjects: 113
Study 29457429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 113
Study 25372235 — intervention group
Group type: EXPERIMENTAL
Intervention: High call completion group
Number of subjects: 151
Study 25372235 — intervention group
Group type: COMPARATOR
Intervention: Low call completion group
Number of subjects: 151
Study 22821361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b plus ribavirin (Peg‐IFN‐α2b/RBV)
Number of subjects: 79
Study 22821361 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 79
Study 21490326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fat emulsion
Number of subjects: 15
Study 21490326 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 18289189 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Care Nurses (CCNs)
Number of subjects: 60
Study 18289189 — intervention group
Group type: COMPARATOR
Intervention: Medical Doctors (MDs)
Number of subjects: 60
Study 18289189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CCNs and MDs)
Number of subjects: 60
Study 16488901 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid (5%) iontophoresis combined with LowDye taping
Number of subjects: 31
Study 16488901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.4%) iontophoresis combined with LowDye taping
Number of subjects: 31
Study 16488901 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) iontophoresis combined with LowDye taping
Number of subjects: 31
Study 12883232 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg/d for 14 days
Number of subjects: 10
Study 12883232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10868320 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT x 2 (twice weekly)
Number of subjects: 0
Study 10868320 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT x 3 (three times weekly)
Number of subjects: 0
Study 10868320 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT (control group)
Number of subjects: 0
Study 9273452 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 178
Study 9273452 — intervention group
Group type: COMPARATOR
Intervention: Open release
Number of subjects: 178
Study 9273452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 178
Study 8255453 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose in water (D5W)
Number of subjects: 748
Study 8255453 — intervention group
Group type: COMPARATOR
Intervention: Half normal saline (0.45S)
Number of subjects: 748
Study 2870753 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neuroleptic medication
Number of subjects: 120
Study 2870753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28498490 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-parametric hierarchical mixture model for gene screening
Number of subjects: 0
Study 28498490 — intervention group
Group type: COMPARATOR
Intervention: Standard regression models with covariates representing subgroups
Number of subjects: 0
Study 26762524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blood pressure target (<130 mm Hg)
Number of subjects: 2610
Study 26762524 — intervention group
Group type: COMPARATOR
Intervention: Higher blood pressure target (130‐149 mm Hg)
Number of subjects: 2610
Study 23539079 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load weighted sled towing (n = 10)
Number of subjects: 21
Study 23539079 — intervention group
Group type: COMPARATOR
Intervention: Light-load weighted sled towing (n = 11)
Number of subjects: 21
Study 23364781 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block with 1 mL kg(‐1) 0.25% levobupivacaine
Number of subjects: 60
Study 19713199 — intervention group
Group type: EXPERIMENTAL
Intervention: 20G vitrectomy
Number of subjects: 40
Study 19713199 — intervention group
Group type: COMPARATOR
Intervention: 25G vitrectomy
Number of subjects: 40
Study 17206693 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported group (SG) receiving social support for 18 months
Number of subjects: 0
Study 17206693 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving no social support
Number of subjects: 0
Study 14966922 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (20,000 IU Epoetin alfa subcutaneously on days 0, 4, and 6) plus iron (100 mg im on days 1-6)
Number of subjects: 27
Study 14966922 — intervention group
Group type: COMPARATOR
Intervention: Iron only
Number of subjects: 27
Study 11347747 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 g three times per day)
Number of subjects: 12
Study 11347747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally three times per day)
Number of subjects: 12
Study 9396564 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 0.32-1.1% AA and 0.24-0.76% DHA
Number of subjects: 0
Study 9396564 — intervention group
Group type: COMPARATOR
Intervention: Commercial formula devoid of AA and DHA
Number of subjects: 0
Study 9396564 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk with fortifier when indicated
Number of subjects: 0
Study 7951238 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6(T) allele
Number of subjects: 236
Study 7951238 — intervention group
Group type: EXPERIMENTAL
Intervention: D6(B)/D6(T) genotype
Number of subjects: 236
Study 7951238 — intervention group
Group type: COMPARATOR
Intervention: Caucasian controls
Number of subjects: 236
Study 2889679 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cinolazepam
Number of subjects: 20
Study 2889679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30671869 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2–4 mg/day
Number of subjects: 0
Study 30671869 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1–4 mg/day (maintenance treatment)
Number of subjects: 0
Study 30671869 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0
Study 30671869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28494892 — intervention group
Group type: COMPARATOR
Intervention: IV-PCA
Number of subjects: 108
Study 28494892 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided single-shot TAP block with 0.2% ropivacaine (20mL) and IV-PCA
Number of subjects: 108
Study 28494892 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TAP block using ultrasound-guidance with 0.2% ropivacaine at a basal rate of 3mL/h, bolus dose of 4mL, and a lockout interval of 30min for 48h postoperatively
Number of subjects: 108
Study 24458265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion therapy
Number of subjects: 21
Study 24458265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold water immersion therapy)
Number of subjects: 21
Study 24684176 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned feedback provided for 107 pedicle tracks, with 15 triggering an intraoperative alarm (evoked electromyogram response in leg muscles to stimulus intensity ≤ 10 mA).
Number of subjects: 71
Study 24684176 — intervention group
Group type: EXPERIMENTAL
Intervention: Break the blind feedback provided 29 times when testing revealed a particularly low threshold (≤ 4 mA) for evoked responses in leg muscles.
Number of subjects: 71
Study 24684176 — intervention group
Group type: COMPARATOR
Intervention: No feedback category for 29 screws that were found to be at least 2 mm medial to the pedicle wall.
Number of subjects: 71
Study 24684176 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implementation of the neuromonitoring strategy during screw placement.
Number of subjects: 71
Study 22424458 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking deep seawater (DSW)
Number of subjects: 42
Study 22424458 — intervention group
Group type: COMPARATOR
Intervention: Reverse osmotic (RO) water
Number of subjects: 42
Study 22424458 — intervention group
Group type: COMPARATOR
Intervention: Magnesium-chloride fortified (MCF) water
Number of subjects: 42
Study 19384122 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial (early) analgesia
Number of subjects: 0
Study 19384122 — intervention group
Group type: COMPARATOR
Intervention: Systemic (late) analgesia
Number of subjects: 0
Study 16972117 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with 10 weeks of multimodal behavior therapy
Number of subjects: 50
Study 16972117 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 50
Study 16202350 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening
Number of subjects: 10000
Study 16202350 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening
Number of subjects: 10000
Study 16202350 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine practice)
Number of subjects: 10000
Study 12660880 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 12660880 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 0
Study 12660880 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 0
Study 12660880 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione treatment
Number of subjects: 0
Study 10080464 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural myocardial infarction (MI)
Number of subjects: 2099